2.4 COPD, Bronchial Asthma & Pulmonary Embolism
Key Takeaways
- Spirometry is essential for diagnosis: COPD is defined by a post-bronchodilator FEV1/FVC ratio <0.70 (persistent airflow limitation), whereas Asthma shows significant bronchodilator reversibility (increase in FEV1 by >12% and >200 mL).
- Acute severe COPD exacerbations are managed with inhaled bronchodilators, systemic corticosteroids (oral Prednisolone 40 mg daily for 5 days), and targeted oxygen therapy maintaining SpO2 88-92% to avoid abolishing the hypoxic drive to breathe.
- According to GINA guidelines, Asthma therapy prioritizes Anti-Inflammatory Reliever (AIR / MART) therapy using low-dose Inhaled Corticosteroid (ICS)-Formoterol across all steps, while acute severe asthma red flags include a normal or elevated PaCO2 indicating respiratory muscle fatigue and impending failure.
- Pulmonary Embolism (PE) risk is stratified using the Wells criteria: low-probability patients undergo D-dimer testing (high negative predictive value), while high-probability patients require CT Pulmonary Angiography (CTPA), with immediate thrombolysis indicated for hemodynamically unstable massive PE.
COPD, Bronchial Asthma & Pulmonary Embolism
1. Obstructive Airway Disease: COPD vs Asthma Differential
Chronic Obstructive Pulmonary Disease (COPD) and Bronchial Asthma are characterized by airflow limitation, but differ fundamentally in etiology, inflammation, and reversibility.
| Feature | Chronic Obstructive Pulmonary Disease (COPD) | Bronchial Asthma |
|---|---|---|
| Primary Age of Onset | Typically $>40 \text{ years}$ | Usually onset in childhood or early adulthood |
| Etiology / Risk Factors | Tobacco smoking ($>90%$), biomass fuel smoke, $\alpha_1$-antitrypsin deficiency | Genetic predisposition, atopy, environmental allergens, occupational exposures |
| Inflammatory Profile | Neutrophilic inflammation (CD8+ T-cells, macrophages) | Eosinophilic inflammation (CD4+ Th2 cells, IgE, Mast cells) |
| Spirometry Definition | Post-bronchodilator $FEV_1/FVC < 0.70$ (Fixed/Irreversible airflow limitation) | Post-bronchodilator $FEV_1$ increase $>12%$ AND $>200 \text{ mL}$ (Reversible) |
| Course & Progression | Progressive, relentless decline in lung function | Variable symptoms, wide nocturnal variations, symptom-free intervals |
High-Yield Clinical Entity ($\alpha_1$-Antitrypsin Deficiency): Consider $\alpha_1$-antitrypsin ($\alpha_1$-AT) deficiency in young non-smokers ($<45 \text{ years}$) presenting with COPD or liver cirrhosis. It causes panacinar emphysema predominantly affecting the lower lobes of the lung (unlike smoking-induced emphysema which is centrilobular and affects the upper lobes).
2. Chronic Obstructive Pulmonary Disease (COPD)
Clinical Phenotypes
- Chronic Bronchitis ("Blue Bloaters"): Defined clinically as productive cough for at least 3 consecutive months in 2 consecutive years. Characterized by mucus hypersecretion, cyanosis, hypoxemia, hypercapnia, pulmonary hypertension, and cor pulmonale (right heart failure with peripheral edema).
- Emphysema ("Pink Puffers"): Defined pathologically as permanent enlargement of airspaces distal to terminal bronchioles with wall destruction. Characterized by severe dyspnea, hyperinflated chest (barrel chest), decreased breath sounds, pursed-lip breathing, and weight loss.
GOLD Spirometric Staging (Based on Post-Bronchodilator $FEV_1$ % Predicted)
- GOLD 1 (Mild): $FEV_1 \ge 80%$ predicted
- GOLD 2 (Moderate): $50% \le FEV_1 < 80%$ predicted
- GOLD 3 (Severe): $30% \le FEV_1 < 50%$ predicted
- GOLD 4 (Very Severe): $FEV_1 < 30%$ predicted
Pharmacotherapy & GOLD ABE Assessment Group Management
- Group A (Low symptoms, 0-1 non-hospitalized exacerbations): Single bronchodilator (SABA, LABA, or LAMA).
- Group B (High symptoms mMRC $\ge 2$ or CAT $\ge 10$, 0-1 non-hospitalized exacerbations): Dual long-acting bronchodilator: LABA + LAMA (e.g., Tiotropium + Formoterol).
- Group E (Exacerbators: $\ge 2$ moderate exacerbations OR $\ge 1$ leading to hospitalization): LABA + LAMA. Add Inhaled Corticosteroid (ICS) if blood eosinophils $\ge 300 \text{ cells/}\mu\text{L}$ (forming Triple Therapy: LABA + LAMA + ICS).
Management of Acute COPD Exacerbation
- Bronchodilators: Nebulized Short-Acting Beta-Agonist (Salbutamol $2.5-5 \text{ mg}$) + Short-Acting Muscarinic Antagonist (Ipratropium Bromide $0.5 \text{ mg}$).
- Systemic Corticosteroids: Oral Prednisolone $40 \text{ mg}$ daily for 5 days (improves recovery and shortens hospital stay).
- Controlled Oxygen Therapy: Administer via Venturi mask targeting $SpO_2$ of 88–92%.
- RATIONALE (UPSC CMS Focus): In chronic severe hypercapnia, the central respiratory center becomes desensitized to high $PaCO_2$. Breathing is driven primarily by hypoxic drive detected by peripheral carotid bodies. Uncontrolled high-flow $O_2$ suppresses hypoxic drive and worsens V/Q mismatch via loss of hypoxic pulmonary vasoconstriction, precipitating severe hypercapnic coma ($PaCO_2 >80 \text{ mmHg}$).
- Antibiotics: Indicated if 2 or more Anthonisen criteria are met (Increased Dyspnea, Increased Sputum Volume, Increased Sputum Purulence). Amoxicillin/Clavulanate or Macrolide for 5 days.
- Non-Invasive Positive Pressure Ventilation (NIV / BiPAP): Indicated if acute hypercapnic respiratory acidosis ($pH < 7.35$ and $PaCO_2 > 45 \text{ mmHg}$) despite medical therapy.
3. Bronchial Asthma & GINA Guidelines
Pathophysiology & Triggers
Chronic airway inflammation driven by IgE mast-cell degranulation, eosinophil recruitment, airway hyperresponsiveness, smooth muscle spasm, and subepithelial basement membrane thickening.
GINA Guidelines Treatment Strategy (Track 1 - Preferred)
Current Global Initiative for Asthma (GINA) guidelines strictly discourage SABA-only treatment due to increased mortality and risk of severe exacerbations.
- Track 1 (Preferred Reliever): Uses Low-dose ICS-Formoterol as needed as the anti-inflammatory reliever (AIR) across ALL steps.
- Step 1-2: As-needed low-dose ICS-Formoterol alone.
- Step 3: Low-dose maintenance ICS-Formoterol + as-needed low-dose ICS-Formoterol (MART - Maintenance and Reliever Therapy).
- Step 4: Medium-dose maintenance ICS-Formoterol + as-needed ICS-Formoterol.
- Step 5: High-dose maintenance ICS-Formoterol + Add-on LAMA (Tiotropium) / Biologic agents (Omalizumab - anti-IgE, Mepolizumab - anti-IL5).
Acute Severe Asthma (Status Asthmaticus) Emergency Management
- Clinical Severity Red Flags: Inability to complete sentences in one breath, Silent chest (absence of wheezing due to severe lack of airflow), Cyanosis, Bradycardia, Exhaustion, $PEFR <33%$ predicted.
- Critical Blood Gas Sign: A normal ($PaCO_2 \approx 40 \text{ mmHg}$) or elevated ($PaCO_2 >45 \text{ mmHg}$) level in a hyperventilating asthmatic patient is a dangerous sign of respiratory muscle fatigue and impending respiratory arrest (normally $PaCO_2$ should be low $\approx 25-30 \text{ mmHg}$ due to hyperventilation).
- Treatment: High-flow $O_2$ (target $SpO_2$ 93-95%), Continuous nebulized Salbutamol + Ipratropium, IV Hydrocortisone $200 \text{ mg}$ or Oral Prednisolone $50 \text{ mg}$, single dose IV Magnesium Sulfate $2 \text{ g}$ over 20 minutes for severe refractory obstruction.
4. Acute Pulmonary Embolism (PE)
Pathophysiology & Virchow's Triad
PE results from thrombi originating from deep vein thrombosis (DVT) of the lower extremities embolizing into the pulmonary arterial bed. Driven by Virchow's Triad: 1) Stasis, 2) Endothelial Injury, 3) Hypercoagulability.
Clinical Presentation
Sudden-onset dyspnea (most common symptom ~85%), pleuritic chest pain, tachypnea (>20/min), tachycardia (>100 bpm), hemoptysis, leg swelling (DVT), syncope (indicates massive PE).
Diagnostic Workup & Wells Score
| Wells Criteria for PE | Score Points |
|---|---|
| Clinical signs and symptoms of DVT | +3.0 |
| PE is #1 diagnosis or equal to alternative diagnosis | +3.0 |
| Heart rate $>100 \text{ beats/min}$ | +1.5 |
| Immobilization $\ge 3$ consecutive days or surgery in past 4 weeks | +1.5 |
| Previous objectively diagnosed PE or DVT | +1.5 |
| Hemoptysis | +1.0 |
| Malignancy (treatment within 6 months or palliative) | +1.0 |
- Wells Score Triage:
- PE Unlikely ($\le 4.0$ points): Order High-Sensitivity D-Dimer. If negative ($<500 \text{ ng/mL}$), PE is ruled out without imaging (high negative predictive value). If positive, proceed to CTPA.
- PE Likely ($>4.0$ points): Proceed directly to CT Pulmonary Angiography (CTPA) (Gold Standard diagnostic imaging test).
Diagnostic Pearls:
- V/Q Scanning: Indicated when CTPA is contraindicated (severe renal failure, IV contrast allergy, pregnancy).
- ECG Findings: Most common finding is Sinus Tachycardia. Classic but rare sign is the S1Q3T3 pattern (McGinn-White sign): Deep S wave in lead I, Q wave in lead III, Inverted T wave in lead III (<20% of cases). Right axis deviation and incomplete/complete RBBB reflect acute right heart strain.
Treatment Protocol
- Hemodynamically Unstable (Massive PE with Shock / SBP <90 mmHg):
- Immediate Thrombolysis with IV Alteplase (tPA 100 mg over 2 hours) or Tenecteplase. Surgical embolectomy if thrombolysis is contraindicated.
- Hemodynamically Stable (Submassive / Low Risk):
- Immediate Anticoagulation: Low Molecular Weight Heparin (Enoxaparin $1 \text{ mg/kg}$ SC bid) or Unfractionated Heparin (UFH) bridged to Direct Oral Anticoagulants (Rivaroxaban $15 \text{ mg}$ bid for 3 weeks then $20 \text{ mg}$ daily, or Apixaban) or Warfarin (target INR 2.0–3.0) for at least 3 to 6 months.
A 55-year-old male smoker presents with progressive exertional shortness of breath. Pulmonary function testing (spirometry) demonstrates an FEV1/FVC ratio of 0.62 after inhaled administration of 400 mcg of Salbutamol. The FEV1 increases by 150 mL (6% predicted change). What is the correct diagnostic interpretation of these spirometric findings?
A 64-year-old male with severe COPD is brought to the emergency department in an acute exacerbation with severe respiratory distress. His arterial blood gas (ABG) on room air shows pH 7.28, PaCO2 68 mmHg, PaO2 50 mmHg, and HCO3- 31 mEq/L. High-flow oxygen via a non-rebreather mask is initiated at 15 L/min. Thirty minutes later, he becomes somnolent and uncooperative, and a repeat ABG shows pH 7.18 and PaCO2 88 mmHg. What is the physiological mechanism responsible for his clinical deterioration?
A 32-year-old female presents to the emergency room with a 3-hour history of acute dyspnea and right-sided pleuritic chest pain. She underwent left knee arthroscopy 10 days ago. Physical exam reveals heart rate 118 bpm, blood pressure 124/78 mmHg, respiratory rate 26/min, and SpO2 91% on room air. Her Wells score for Pulmonary Embolism is calculated to be 6.0 points (High probability). What is the most appropriate next diagnostic step?
A 24-year-old known asthmatic patient is brought to the emergency department in severe acute respiratory distress. She is unable to speak and appears exhausted. On auscultation, breath sounds are markedly reduced bilaterally with a complete absence of wheezing ('silent chest'). Arterial blood gas analysis reveals pH 7.34, PaCO2 42 mmHg, and PaO2 62 mmHg on 4 L/min nasal cannula oxygen. How should the PaCO2 value of 42 mmHg be interpreted in this clinical context?